Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2003 Apr;12(2):123–125. doi: 10.1080/0962935031000097736

Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index.

Gabriele Di Lorenzo 1, Sebastiano Gangemi 1, Rosaria Alba Merendino 1, Paola Lucia Minciullo 1, Serafina Paola Cannavò 1, Nicola Martinelli 1, Pasquale Mansueto 1, Giovanni Battista Rini 1, Roberto Corrocher 1, Maria Luisa Pacor 1
PMCID: PMC1781600  PMID: 12775363

Abstract

The value of CD30 and the soluble circulating fragment of CD30 (sCD30) for atopic dermatitis (AD) remains unclear. In particular, little is known about the effects of age, duration of disease and Scoring Atopic Dermatitis index (SCORAD) on the levels of serum sCD30 in patients affected by AD. In the present study, we have analysed serum sCD30 levels of adult patients affected by AD. The study's population includes 18 non-smoking outpatients, with a diagnosis of AD. As a control group we studied 18 non-atopic subjects from laboratory staff, matched for sex and age. These subjects had no history of AD, urticaria or seasonal or perennial rhinitis or asthma, and had negative skin prick test to a panel of allergens. The sCD30 serum levels were clearly higher in patients affected by AD (14.2+/-9.0 IU/ml) than in healthy subjects (1.2+/-0.8 IU/ml) (p<0.001). No differences were observed between males and females affected by atopic dermatitis, regarding age, duration of disease and SCORAD. Significant correlations were found between serum levels of sCD30 levels and age (r=-0.55; 95% confidence interval (CI) for r (Fisher's z transformed)=-0.81 to -0.12; p=0.01), duration of the disease (months) (r=-0.64; 95% CI for r (Fisher's z transformed)=-0.85 to -0.24; p=0.004) and SCORAD (r=-0.74; 95% CI for r (Fisher's z transformed)=-0.89 to -0.42; p=0.004). As demonstrated by the close correlation with age, duration of disease and SCORAD, serum levels of sCD30 appear to be an additional marker for the follow-up of AD.

Full Text

The Full Text of this article is available as a PDF (81.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caproni M., Salvatore E., Cardinali C., Brazzini B., Fabbri P. Soluble CD30 and cyclosporine in severe atopic dermatitis. Int Arch Allergy Immunol. 2000 Apr;121(4):324–328. doi: 10.1159/000024346. [DOI] [PubMed] [Google Scholar]
  2. D'Elios M. M., Romagnani P., Scaletti C., Annunziato F., Manghetti M., Mavilia C., Parronchi P., Pupilli C., Pizzolo G., Maggi E. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol. 1997 May;61(5):539–544. [PubMed] [Google Scholar]
  3. Gerli R., Lunardi C., Vinante F., Bistoni O., Pizzolo G., Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 2001 Feb;22(2):72–77. doi: 10.1016/s1471-4906(00)01829-9. [DOI] [PubMed] [Google Scholar]
  4. Grewe M., Gyufko K., Schöpf E., Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet. 1994 Jan 1;343(8888):25–26. doi: 10.1016/s0140-6736(94)90879-6. [DOI] [PubMed] [Google Scholar]
  5. Hamid Q., Boguniewicz M., Leung D. Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994 Aug;94(2):870–876. doi: 10.1172/JCI117408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Higashi N., Bang K., Gesser B., Lund M., Thestrup-Pedersen K. Cytokine expression of skin T-lymphocytes from patients with atopic dermatitis. Acta Derm Venereol. 2001 Jan-Feb;81(1):3–7. doi: 10.1080/00015550117325. [DOI] [PubMed] [Google Scholar]
  7. Jung T., Witzak K., Dieckhoff K., Zachmann K., Heidrich S., Aversa G., Neumann C. IFN-gamma is only partially restored by co-stimulation with IL-12, IL-2, IL-15, IL-18 or engagement of CD28. Clin Exp Allergy. 1999 Feb;29(2):207–216. doi: 10.1046/j.1365-2222.1999.00482.x. [DOI] [PubMed] [Google Scholar]
  8. Kägi M. K., Joller-Jemelka H., Wüthrich B. Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology. 1992;185(2):88–92. doi: 10.1159/000247419. [DOI] [PubMed] [Google Scholar]
  9. Kägi M. K., Wüthrich B., Montano E., Barandun J., Blaser K., Walker C. Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol. 1994;103(4):332–340. doi: 10.1159/000236651. [DOI] [PubMed] [Google Scholar]
  10. Leung D. Y. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 2):S99–108. doi: 10.1016/s0091-6749(99)70051-5. [DOI] [PubMed] [Google Scholar]
  11. Ohmen J. D., Hanifin J. M., Nickoloff B. J., Rea T. H., Wyzykowski R., Kim J., Jullien D., McHugh T., Nassif A. S., Chan S. C. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol. 1995 Feb 15;154(4):1956–1963. [PubMed] [Google Scholar]
  12. Sánchez-Guerrero I., Albaladejo M. D., García-Alonso A. M., Muro M., Hernández J., Alvarez M. R. Soluble CD23 (sCD23) serum levels and lymphocyte subpopulations in peripheral blood in rhinitis and extrinsic and intrinsic asthma. Allergy. 1994 Sep;49(8):587–592. doi: 10.1111/j.1398-9995.1994.tb00123.x. [DOI] [PubMed] [Google Scholar]
  13. Tanaka Y. [Pathogenesis and guidelines for therapy of atopic dermatitis]. Nihon Rinsho. 2001 Jun;59(6):1219–1227. [PubMed] [Google Scholar]
  14. Trautmann A., Akdis M., Bröcker E. B., Blaser K., Akdis C. A. New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis. Trends Immunol. 2001 Oct;22(10):530–532. doi: 10.1016/s1471-4906(01)02004-x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES